Core Viewpoint - The report presented at the AASLD annual meeting is a significant showcase of the company's progress in innovative drug development for hepatitis B treatment, aimed at gaining international attention in the field of hepatology and fostering friendly international exchanges and discussions [1] Group 1 - The company is committed to steadily advancing the clinical research and development of innovative hepatitis B drugs [1] - The company will fulfill its obligation to disclose information regarding the progress of innovative drugs in a timely manner, in accordance with regulations [1]

Core Viewpoint - The 76th American Association for the Study of Liver Diseases (AASLD) annual meeting highlighted significant advancements in hepatitis B treatment, particularly through the innovative drug Hepcludex developed by Shanghai Hepu Pharmaceutical, which has shown promising results in clinical trials [1] Group 1: Clinical Trial Results - Hepcludex has achieved breakthrough progress in its Phase II randomized double-blind clinical trial for chronic hepatitis B [1] - The drug demonstrated the ability to reverse interferon resistance in patients with "big three positive" hepatitis B, a significant milestone in treatment [1] - Some patients in the trial achieved cccDNA clearance, meeting the highest international standard for hepatitis B cure known as sterilizing cure [1]

Core Viewpoint - Guangshentang (300436) is actively conducting Phase III clinical trials for its innovative hepatitis B drug, Nairu Kewei GST-HG141, targeting patients with poor antiviral response to chronic hepatitis B (CHB) treatment [1] Company Summary - The company is focusing on the development of Nairu Kewei GST-HG141 as a combination therapy for chronic hepatitis B patients [1] - The research scope of the drug does not include treatment for hepatitis C (HCV) [1]